<SEC-DOCUMENT>0001140361-24-002903.txt : 20240119
<SEC-HEADER>0001140361-24-002903.hdr.sgml : 20240119
<ACCEPTANCE-DATETIME>20240119160530
ACCESSION NUMBER:		0001140361-24-002903
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20231211
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240119
DATE AS OF CHANGE:		20240119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562020050
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		24545596

	BUSINESS ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(619) 949-3681

	MAIL ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>ef20019132_8ka.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:gyre="http://ir.catalystbiosciences.com/20231211" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_31431eae65574d029d1bb18e2d8f363f" contextRef="c20231211to20231211" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_715a27db599444ffa760a2e5adc48c09" contextRef="c20231211to20231211">0001124105</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="gyre-20231211.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20231211to20231211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-11</xbrli:startDate><xbrli:endDate>2023-12-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

    <div style="text-align: center; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_e338b480561949179b54e82ead96a3d4" contextRef="c20231211to20231211">8-K/A</ix:nonNumeric></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Amendment No. 1)</div>

    <div style="text-align: center; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported): <span style="font-family: 'Times New Roman'; font-weight: bold;">January 15, 2024 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_4ad4d7bed0d541a5884618667ea24440" contextRef="c20231211to20231211" format="ixt:date-monthname-day-year-en">December 11, 2023</ix:nonNumeric>)</span></div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_94e592c3c7434260a80c7e0be88622d6" contextRef="c20231211to20231211">Gyre Therapeutics, Inc.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5aea80d44c2443688a278cf11e5ba6e7" contextRef="c20231211to20231211" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 34%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_19c105802de6462bb420ed4e4ac05b54" contextRef="c20231211to20231211">000-51173</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_6f0d2c0f746a45b2b60496cd399d7a46" contextRef="c20231211to20231211">56-2020050</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_1f82017e2439400b9da329d7adb130db" contextRef="c20231211to20231211">12770 High Bluff Drive</ix:nonNumeric><br />
            </div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_4509eaad04094187b871a2a62dbfa7d9" contextRef="c20231211to20231211">Suite 150</ix:nonNumeric><br />
            </div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_bbe31d698a074fa4ac60f4d6f43a1952" contextRef="c20231211to20231211">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_b2d1e3af847a40048d7c248eba4e59a7" contextRef="c20231211to20231211">CA</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_ec5016c69836479091e938597c4917d1" contextRef="c20231211to20231211">92130</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">(Address of principal executive offices)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_33bdfe32d3f24326b0dc92f0012f7ac5" contextRef="c20231211to20231211">619</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_d0d31ab9b9cb4ba3951215bb6dc82046" contextRef="c20231211to20231211">949-3681</ix:nonNumeric></span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">N/A</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions (<span style="font-family: 'Times New Roman'; font-style: italic;">see</span> General Instruction A.2. below):</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_1f745627c6654c6895325876c6365610" contextRef="c20231211to20231211" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_4f7caaeed54a4ccc881dc2d1982d9605" contextRef="c20231211to20231211" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_37ea596f70db409d8bbd88918a944f34" contextRef="c20231211to20231211" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_9d0db4d3aafa4c50a7c70baa8c517c39" contextRef="c20231211to20231211" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; white-space: nowrap;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title of each class</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Trading Symbol(s)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_6eb13dac33fd492eaf6a26ccfdc5f110" contextRef="c20231211to20231211">Common Stock</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_e636396c875741c3bf176385e303456c" contextRef="c20231211to20231211">GYRE</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_0f2de5a65ab5457cbff86b15b7b7f598" contextRef="c20231211to20231211">NASDAQ</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
      or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_8e548309691b45f8abf8051e94c31cb9" contextRef="c20231211to20231211" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXPLANATORY NOTE</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This Amendment No. 1 to Current Report on Form 8-K (this &#8220;Form 8-K/A&#8221;) amends the Current Report on Form 8-K filed by Gyre Therapeutics, Inc. (the &#8220;Company&#8221;) on December
      11, 2023 (the &#8220;Initial Form 8-K&#8221;). The Initial Form 8-K reported the retirement and resignation of Dr. Charles Wu as the Company&#8217;s Chief Executive Officer and as a member of the board of directors (the &#8220;Board&#8221;) of the Company, and Dr. Han Ying&#8217;s
      appointment as the Company&#8217;s Chief Executive Officer, effective January 15, 2024, to succeed Dr. Wu. Pursuant to Instruction 2 to Item 5.02 of Form 8-K, this Form 8-K/A is being filed to (i) disclose the Company&#8217;s vacancy on its Audit Committee, (ii)
      disclose committee assignments for Drs. Han Ying and Renate Parry, which had not been determined at the time of filing of the Initial Form 8-K and (iii) describe the employment agreement for Dr. Ying, which had not been executed at the time of filing
      of the Initial Form 8-K.</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 3.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard&#894; Transfer of Listing.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">On January 15, 2024, the Company notified the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that, following Dr. Charles Wu&#8217;s retirement and resignation as the Company&#8217;s Chief
      Executive Officer and as a member of the Board, and Dr. Han Ying&#8217;s appointment as the Company&#8217;s Chief Executive Officer, effective on January 15, 2024, to succeed Dr. Wu, Dr. Ying stepped down as a member of the Audit Committee of the Company. The
      Company has a vacancy on its Audit Committee and intends to rely on the cure period set forth in the Nasdaq Listing Rules while it recruits a new Audit Committee member, as described in more detail below.</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">On January 17, 2024, the Company received a letter from Nasdaq confirming that t</span><span style="font-size: 10pt;">he Company is no longer in compliance with Nasdaq&#8217;s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605, which requires that the audit committee of a listed company be comprised of at least
        three &#8220;independent directors&#8221; (as defined in Nasdaq Listing Rule 5605(a)(2))<span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">. </span>Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company intends to rely on the cure period to
        reestablish compliance with Nasdaq Listing Rule 5605. The cure period <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">is generally defined as until the earlier of the Company&#8217;s next annual meeting of stockholders or July 15,
          2024.</span></span></div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Board is in the process of identifying and selecting a new member of the Board who qualifies as &#8220;independent&#8221; and would meet the audit committee
      criteria set forth in Nasdaq Listing Rule 5605. The Board intends to comply fully with Nasdaq audit committee requirements by or before the end of the cure period described above.</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#8201;5.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointments of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br />
      </span></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Effective as of January 15, 2024, the Board appointed Dr. Renate Parry as Chair of the Board&#8217;s Compensation Committee, replacing Dr. Han Ying, who stepped down as Chair and
      member of such committee. In addition, on January 15, 2024, Dr. Ying stepped down as a member of the Board&#8217;s Audit Committee.</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On January 15, 2024, the Company entered into an employment agreement with Dr. Ying (the &#8220;Employment Agreement&#8221;) to serve as the Company&#8217;s Chief Executive
      Officer. The Employment Agreement provides for Dr. Ying&#8217;s at-will employment and an annual base salary of $350,000, an annual bonus to be determined annually by the Board or the Compensation Committee, as well as his ability to participate in the
      Company&#8217;s employee benefit plans generally. In the event of the termination of Dr. Ying&#8217;s employment by the Company without &#8220;Cause&#8221; or by Dr. Ying for &#8220;Good Reason&#8221; (as each term is defined in the Employment Agreement), subject to Dr. Ying&#8217;s
      execution without revocation of a release of claims against the Company and its affiliates, Dr. Ying will be entitled to: (i) an amount equal to Dr. Ying&#8217;s then-current annual base salary, paid in installments over twelve months, (ii) for up to
      twelve months, reimbursement of premium payments, as if Dr. Ying had remained an active employee, for any COBRA coverage that he timely elects and (iii) accelerated vesting of the portion of any outstanding equity awards held by Dr. Ying as of the
      termination date that were scheduled to vest during the twelve month period following Dr. Ying&#8217;s termination date, had he remained employed during such time.</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing summary of the Employment Agreement does not purport to be a complete description of the Employment Agreement and is qualified in its entirety
      by reference to the full text of the Employment Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br />
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6%; vertical-align: bottom; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">No.</div>
          </td>

    <td style="width: 94%; vertical-align: bottom; font-size: 10pt; white-space: nowrap;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: middle; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; font-size: 10pt; white-space: nowrap;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><a href="ef20019132_ex10-1.htm">10.1</a></div>
          </td>

    <td style="width: 94%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Employment Agreement, dated January 15, 2024, by and between Han Ying, Ph.D. and Gyre Therapeutics, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: middle; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; font-size: 10pt; white-space: nowrap;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">104</div>
          </td>

    <td style="width: 94%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">The cover page from the Company&#8217;s Current Report on Form 8-K formatted in Inline XBRL.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

    <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br />
      </span></div>

    <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</div>

    <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br />
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">GYRE THERAPEUTICS, INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Date: <span style="font-family: 'Times New Roman'; font-weight: bold;">January 19, 2024</span></div>
          </td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
          </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ Han Ying, Ph.D.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name:</div>
          </td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Han Ying, Ph.D.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title:</div>
          </td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Chief Executive Officer</div>
          </td>

  </tr>


</table>
    <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br />
      </span></div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ef20019132_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;"> Exhibit 10.1</font><font style="font-size: 10pt;"><br>
    </font></div>
  <div style="text-align: left;"><font style="font-weight: bold;"> </font><br>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Execution</div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EMPLOYMENT AGREEMENT</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS EMPLOYMENT AGREEMENT (this &#8220;<font style="font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;), dated as of January 15, 2024, by and between
      Gyre Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), and Han Ying (the &#8220;<font style="font-family: 'Times New Roman';"><u>Executive</u></font>&#8221;).</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>W I T N E S </u><u>S</u><u> E T H:</u></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, upon the terms and conditions
      hereinafter set forth; and</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, effective as of the date hereof, this Agreement supersedes all prior agreements and understandings (including verbal agreements) between the
      Executive and the Company and/or its Affiliates regarding the terms and conditions of the Executive&#8217;s employment with the Company and/or its Affiliates.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and for good and valuable consideration, the receipt of which
      is hereby acknowledged, the parties hereto, each intending to be legally bound hereby, agree as follows:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Employment</u></font>. On the terms and subject to the conditions set forth herein, the Company hereby agrees to employ the Executive, and the Executive hereby agrees to accept such employment, for the Employment Term (as defined
          below). During the Employment Term, the Executive shall serve as the Chief Executive Officer of the Company and shall report to the Board of Directors of the Company (the &#8220;<font style="font-family: 'Times New Roman';"><u>Board</u></font>&#8221;),
          performing such duties and responsibilities as are customarily attendant to such position with respect to the business of the Company and its subsidiaries and such other duties and responsibilities normally accorded to such a position, as may
          from time to time be reasonably assigned by the Board.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Performance</u></font>. The Executive shall serve the Company and its subsidiaries and Affiliates faithfully and to the best of his ability and, subject to <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, shall devote his full business time, energy, experience and talents to the business of the Company and its subsidiaries and Affiliates.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Employment Term</u></font>. Subject to earlier termination pursuant to <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, the term of employment of the Executive hereunder shall
          begin on the date hereof (the &#8220;<font style="font-family: 'Times New Roman';"><u>Commencement Date</u></font>&#8221;), and shall continue through the date which is three (3) years following the Commencement Date; <font style="font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-family: 'Times New Roman';"><u>however</u></font>, that beginning on the three (3)-year anniversary of the Commencement Date, and on each subsequent anniversary of the Commencement Date, such
          term shall be automatically extended by an additional one (1)-year period, unless the Company or the Executive provides notice to the other party no less than sixty (60) days in advance of the expiration of the term, that it or he does not desire
          to extend the term of this Agreement, in which case, the term of employment hereunder shall terminate as of the end of the term, as applicable (the &#8220;<font style="font-family: 'Times New Roman';"><u>Employment Term</u></font>&#8221;); <font style="font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-family: 'Times New Roman';"><u>however</u></font>, that the provisions of <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> of this
          Agreement shall survive any termination of this Agreement or termination of the Executive&#8217;s employment hereunder.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%-%-%-->
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Principal Location</u></font>. The Executive&#8217;s principal place of employment shall be the Company&#8217;s offices located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130 USA, subject to reasonable
          travel.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Compensation and Benefits</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Base Salary</u></font>. As compensation for his services hereunder, during the Employment Term, the Company shall pay the Executive a base salary, payable in equal installments in accordance with
          Company payroll procedures, at an annual rate of $350,000 (&#8220;<font style="font-family: 'Times New Roman';"><u>Base Salary</u></font>&#8221;). The Executive&#8217;s annual Base Salary is subject to increase to be mutually agreed by the Executive and the
          Company from time to time.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Annual Bonus</u></font>. The Executive shall be eligible to participant in the Company&#8217;s annual bonus program in effect from time to time. The amount of such bonus (&#8220;<font style="font-family: 'Times New Roman';"><u>Annual Bonus</u></font>&#8221;) shall be based on the performance of the Company and its Affiliates and/or Executive, with specific performance targets and amounts to be determined annually by the Board or the Compensation Committee
          of the Board.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Benefits</u></font>. During the Employment Term, the Executive shall, subject to and in accordance with the terms and conditions of the applicable plan documents and all applicable laws, be eligible to
          participate in all of the employee benefit plans, practices, policies and arrangements the Company makes available from time to time to its other similarly situated employees.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Business Expenses</u></font>. During the Employment Term, the Executive shall be reimbursed by the Company for all reasonable and necessary business expenses actually incurred by him in performing his
          duties hereunder. All payments under this paragraph (d) of this <font style="font-family: 'Times New Roman';"><u>Section 5</u></font> will be made in accordance with policies established by the Company from time to time and subject to receipt by
          the Company of appropriate documentation.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Termination of Employment</u></font>. The following terms shall govern (x) the termination of the Executive&#8217;s employment, and (y) certain of the Executive&#8217;s obligations following the Executive&#8217;s
          termination of employment.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Death; Disability</u></font><font style="font-size: 10pt;">. If the Executive&#8217;s employment with the Company terminates by reason of the Executive&#8217;s death or the Executive&#8217;s Disability, then the Company will pay
        to the Executive&#8217;s estate, in the case of the Executive&#8217;s death, or to the Executive or the Executive&#8217;s guardian, in the case of the Executive&#8217;s Disability, the Executive&#8217;s Accrued Compensation (as defined below) within 30 days after the
        Executive&#8217;s termination (with the payment date during such 30 day period to be determined by the Company in its sole discretion, except as required by applicable law).</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Termination by the Company for Cause or Voluntary Termination by the Executive</u></font>. If (i) the Company terminates the Executive&#8217;s employment for Cause (as defined below), or (ii) the Executive
          voluntarily terminates the Executive&#8217;s employment without Good Reason, then the Company shall pay the Executive&#8217;s Accrued Compensation to the Executive through the date the Executive&#8217;s employment terminates within the time period permitted by
          applicable law.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-2-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Termination by the Company Without Cause or by the Executive for Good Reason</u></font><font style="font-size: 10pt;">. If the Executive&#8217;s employment is terminated (i) by the Company without Cause and for a
        reason other than the Executive&#8217;s death or Disability, or (ii) by the Executive for Good Reason, then the Company shall pay to the Executive within 30 days after the Executive&#8217;s termination (with the payment date during such 30 day period to be
        determined by the Company in its sole discretion, except as required by applicable law) the Executive&#8217;s Accrued Compensation. The Company shall also provide the following additional payments and benefits:</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(1)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The Company shall pay to the Executive a
          cash payment equal to the then-current Base Salary, payable in installments in accordance with the Company&#8217;s standard payroll practice over a period of twelve (12) months after the date the Executive&#8217;s employment terminates;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(2)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">To
          the extent the Executive and/or the Executive&#8217;s covered dependent(s) timely elect to continue to participate in the Company&#8217;s group health plan(s) pursuant to the Consolidated Omnibus Reconciliation Act of 1985, as amended (&#8220;<font style="font-family: 'Times New Roman';"><u>COBRA</u></font>&#8221;) after the Executive&#8217;s termination of employment, unless prohibited by applicable law, the Company will directly pay or reimburse the applicable COBRA premiums paid by the Executive
          and the Executive&#8217;s covered dependent(s) so that the Executive and the Executive&#8217;s covered dependent(s) enjoy coverage at the same benefit level and to the same extent and for the same effective contribution, if any, as participation is available
          to other executive officers of the Company, commencing on the date the Executive&#8217;s employment terminates and ending on the earliest to occur of: (A) the twelve (12) month anniversary of such termination date, (B) the date the Executive first
          becomes eligible for group health insurance coverage for any reason, or (C) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination; and</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(3)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Outstanding
          equity incentive awards with respect to shares of the Company&#8217;s common stock held by the Executive that would have vested in the twelve (12) months following the date the Executive&#8217;s employment terminates had the Executive remained employed by
          the Company will become fully vested as of the date the Executive&#8217;s employment terminates.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Other Programs</u></font><font style="font-size: 10pt;">. Except as otherwise provided in this Agreement, the Executive&#8217;s entitlements under applicable plans and programs of the Company following termination of
        the Executive&#8217;s employment will be determined under the terms of those plans and programs.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Conditions to Receipt of Benefits Under Section 6</u>.</font><font style="font-size: 10pt;"> Notwithstanding anything in this Agreement to the contrary, other than the payment of the Executive&#8217;s Accrued
        Compensation through the date of termination of the Executive&#8217;s employment, the Executive shall not be entitled to any termination payments or benefits under this <u><font style="font-family: 'Times New Roman';">Section 6</font></u> unless and
        until the Executive (or the representative of the Executive&#8217;s estate, in the case of termination due to the Executive&#8217;s death) executes and delivers to the Company, within forty-five (45) days of the date of termination of the Executive&#8217;s
        employment, a unilateral general release of all known and unknown claims against the Company and its officers, directors, employees, agents and Affiliates in a form acceptable to the Company, and such release becomes fully effective and irrevocable
        under applicable law. For the avoidance of doubt, in the event the Executive violates the restrictions set forth in <u><font style="font-family: 'Times New Roman';">Section 7</font></u> of this Agreement, the Company shall cease making or
        providing any payments or benefits otherwise payable or deliverable under this <u><font style="font-family: 'Times New Roman';">Section 6</font></u>.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-3-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Resignation as Officer or Director</u></font>. Upon a termination of employment, unless requested otherwise by the Company, the Executive shall resign each position (if any) that the Executive then
          holds as a director or officer of the Company or of any Affiliates of the Company with the exception of any such positions concurrently held at other GNI Group companies. The Executive&#8217;s execution of this Agreement shall be deemed the grant by
          the Executive to the officers of the Company of a limited irrevocable power of attorney (which is deemed coupled with an interest) to sign in the Executive&#8217;s name and on the Executive&#8217;s behalf any such documentation as may be required to be
          executed solely for the limited purposes of effectuating such resignations as an officer.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Certain Definitions</u></font><font style="font-size: 10pt;">. For purposes of this Agreement, the following terms shall have the meanings set forth herein:</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(1)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;Affiliate&#8221;
          of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(2)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">&#8220;Accrued
          Compensation&#8221; means (A) any Base Salary payable to the Executive pursuant to this Agreement, accrued up to and including the last day of the Executive&#8217;s employment with the Company, (B) any employee benefits to which the Executive is entitled
          upon termination of his employment with the Company in accordance with the terms and conditions of the applicable plans of the Company, (C) reimbursement for any unreimbursed business expenses incurred by the Executive prior to his date of
          termination, and (D) to the extent permitted by law, less any advances made to the Executive.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(3)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;Cause&#8221;
          shall mean the Executive&#8217;s (A) indictment for, conviction of or plea of <font style="font-family: 'Times New Roman'; font-style: italic;">nolo contendere</font> to any felony or other crime involving fraud, dishonesty or acts of moral turpitude,
          (B) commission of any act or omission involving dishonesty, disloyalty or fraud with respect to the Company or any of its customers or suppliers, (C) substantial failure to timely perform duties reasonably directed by the Board (other than due to
          the Executive&#8217;s Disability), (D) engaging or having engaged in any acts constituting breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of the Executive&#8217;s services provided hereunder, or (E)
          material breach of this Agreement, any other material agreement with the Company, or any internal policies or procedures of the Company in effect from time to time; provided, however, the conditions described in sub-clauses (C) and (E) above
          shall not constitute Cause unless the Company first provides written notice to the Executive of the occurrence of the applicable condition and the Executive fails to cure such condition within ten (10) days after receipt of such written notice
          and, if uncured, the termination shall be effective as of the end of such cure period.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(4)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;Disability&#8221;
          means that (A) the Executive qualifies for long-term disability benefits under a long-term disability program sponsored by the Company in which employees participate generally or (B) if the Company does not sponsor such a long-term disability
          program, the Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of
          not less than twelve (12) months.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-4-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(5)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The
          Executive shall be deemed to have &#8220;Good Reason&#8221; to terminate the Executive&#8217;s employment hereunder if, without the Executive&#8217;s prior written consent, (i) the Company materially reduces the Executive&#8217;s duties or responsibilities as Chief Executive
          Officer, (ii) the Company materially reduces Executive&#8217;s then-current Base Salary or target annual incentive award as set forth herein (in each case, other than as part of an across-the-board reduction applicable to all &#8220;named executive officers&#8221;
          of the Company (as defined under Item 402 of Regulation S-K and to the extent employed by the Company at that time)), or (iii) the Company materially breaches a material term of this Agreement. Prior to terminating for Good Reason, the Executive
          shall be required to provide the Company with 30 days&#8217; advance written notice of the Executive&#8217;s intention to terminate employment for Good Reason, and the Company shall be permitted to cure any events giving rise to such Good Reason during such
          30 day period, after which, if such event remains uncured, the Executive&#8217;s employment must terminate within 30 days.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(6)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;Governmental
          Entity&#8221; means any federal, state, local or foreign government or subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority, instrumentality, agency,
          commission or body.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(7)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;Person&#8221;
          means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including any Governmental Entity.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Covenants of the Executive</u></font>. The Executive acknowledges that in the course of his employment with the Company he has become and will continue to become familiar with the Company&#8217;s and its
          subsidiaries&#8217; and Affiliates&#8217; trade secrets and with other confidential and proprietary information concerning the Company and its subsidiaries and Affiliates, and that his services are of special, unique and extraordinary value to the Company
          and its subsidiaries and Affiliates. Therefore, the Company and the Executive mutually agree that it is in the interest of both parties for the Executive to enter into the restrictive covenants set forth in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> to, among other things, protect the legitimate business interests of the Company and those of its subsidiaries and Affiliates, and that such restrictions and covenants contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> are reasonable in geographical and temporal scope and in all other respects given the nature and scope of the Executive&#8217;s duties and the nature and scope of the Company&#8217;s and its
          subsidiaries&#8217; and Affiliates&#8217; businesses and that such restrictions and covenants do not and will not unduly impair the Executive&#8217;s ability to earn a living after termination of his employment with the Company. The Executive further acknowledges
          and agrees that (i) the Company would not have entered into this Agreement but for the restrictive covenants of the Executive set forth in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, and (ii) such restrictive
          covenants have been made by the Executive in order to induce the Company to enter into this Agreement. For purposes of this Agreement, &#8220;<font style="font-family: 'Times New Roman';"><u>Company Group</u></font>&#8221; shall mean the Company and its
          subsidiaries.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-5-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>During Employment</u></font>. During the Employment Term, the Executive shall not engage in any other business activity that, in the reasonable judgment of the Board, conflicts with the duties of the
          Executive as an employee of the Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage. Specifically, but without limiting the foregoing, the Executive agrees not to work or provide services, in any
          capacity, whether as a director, employee, independent contractor or otherwise, whether with or without compensation, to any individual or entity. During the Employment Term, the Executive shall not be party to any agreement or understanding,
          written or oral and will not be subject to or agree to or enter into any restriction, which in either case, could prevent the Executive from entering into this Agreement or performing the duties and obligations hereunder.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Post-Employment Restrictions</u></font>. During the Employment Term and for a period of twelve (12) months following the termination of the Executive&#8217;s employment with the Company Group, the Executive
          will not, and will not assist any other individual or entity to, (i) solicit for hire any current employee, representative, independent contractor, consultant or agent of any member of the Company Group or any individual who served in any such
          capacity in the previous twelve (12) months (each such individual, a &#8220;<font style="font-family: 'Times New Roman';"><u>Service Provider</u></font>&#8221;), (ii) induce or attempt to induce any employee, representative, independent contractor,
          consultant or agent of any member of the Company Group to terminate his or her relationship with the Company Group, or (iii) take any action to materially assist or aid any other Person in soliciting for or attempting to hire or hiring any
          Service Provider.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Confidential Information</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The
          Executive will not, and will use his reasonable best efforts to cause his Affiliates not to, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any Person, other than in the course of the Executive&#8217;s assigned
          duties and for the benefit of the Company Group, any Confidential Information. The foregoing will not apply to information that (i) is or was known to the public prior to its disclosure to the Executive; (ii) becomes generally known to the public
          subsequent to disclosure to the Executive through no wrongful act of the Executive or any of his Affiliates; (iii) the Executive or his Affiliates is required to disclose by applicable law, regulation, recognized subpoena power, any governmental
          body or any other legal process (<font style="font-family: 'Times New Roman';"><u>provided</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>that</u></font>, to the extent permitted by applicable law, recognized subpoena power, any
          governmental body or any other legal process, the Executive or his Affiliates, as applicable, provide the Company with prior notice of the contemplated disclosure and cooperate with the Company at its expense in seeking a protective order or
          other appropriate protection of such information); (iv) is lawfully acquired by the Executive from sources which are not prohibited from disclosing such information; or (v) is reasonably required to be disclosed by the Executive in any proceeding
          to enforce the Executive&#8217;s rights under this Agreement or any other agreement between the Executive and any member of the Company Group or any of their respective Affiliates. The Executive understands that this restriction shall continue to apply
          after his employment terminates, regardless of the reason for such termination. The confidentiality obligation under this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> shall not apply to information which is generally
          known or readily available to the public at the time of disclosure or becomes generally known through no wrongful act on the part of the Executive or any other Person having an obligation of confidentiality to the Company or any of its
          Affiliates. For purposes of this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, &#8220;<font style="font-family: 'Times New Roman';"><u>Confidential Information</u></font>&#8221; means any proprietary information concerning the
          business, and the Company Group, including, without limitation: all data, information, ideas, concepts, discoveries, trade secrets, inventions (whether or not patentable or reduced to practice), innovations, improvements, know-how, developments,
          techniques, methods, processes, treatments, drawings, sketches, specifications, designs, patterns, models, plans and strategies, and all other confidential or proprietary information or trade secrets in any form or medium (whether merely
          remembered or embodied in a tangible or intangible form or medium) whether now or hereafter existing, relating to or arising from the past, current or potential business, activities and/or operations of the Company Group, including, without
          limitation, any such information relating to or concerning finances, sales, marketing, advertising, transition, promotions, pricing, personnel, customers, suppliers, vendors, partners and/or competitors.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-6-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">All
          documents, records, tapes and other media of every kind and description relating to the Confidential Information of the Company Group and any copies, in whole or in part, thereof (the &#8220;<font style="font-family: 'Times New Roman';"><u>Documents</u></font>&#8221;),
          whether or not prepared by the Executive, shall be the sole and exclusive property of the Company and its Affiliates. The Executive shall safeguard all Documents and shall surrender to the Company at the time his employment terminates, or at such
          earlier time or times as the Board may specify, all Documents then in the Executive&#8217;s possession or control. Notwithstanding the foregoing, the Executive shall be permitted to retain: (A) personal papers and other materials of a personal nature,
          (B) information showing the Executive&#8217;s Base Salary, Annual Bonus, or relating to reimbursement of expenses, (C) copies of plans, programs and agreements relating to Executive&#8217;s employment, or termination thereof, with the Company which the
          Executive received in the Executive&#8217;s capacity as a participant, (D) copies of this Agreement, and any other written agreement between the Executive and the Company, and (E) any personal contacts; provided, however, that in each case of
          subsections (A) through (E), such papers or materials do not include any Confidential Information as defined herein.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">18
          U.S.C. &#167; 1833(b) provides: &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#8212;(A) is made&#8212;(i) in confidence to a Federal, State, or local government
          official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if
          such filing is made under seal.&#8221; Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. &#167; 1833(b). Accordingly, the parties to this
          Agreement have the right to disclose in confidence trade secrets to federal, state, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. The parties also have the
          right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-7-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Company IP; Work Product</u></font>. The Executive hereby assigns and agrees to assign to the Company (or as otherwise directed by the Company) the Executive&#8217;s full right, title and interest in and to
          all Intellectual Property (as defined below) which now exists or which hereafter arises. The Executive agrees to execute any and all applications for domestic and foreign patents, copyrights or other proprietary rights and to do such other acts
          (including without limitation the execution and delivery of instruments of further assurance or confirmation) requested by the Company to assign the Intellectual Property to the Company and to permit the Company to enforce any patents, copyrights
          or other proprietary rights to the Intellectual Property. The Executive will not charge the Company for time spent in complying with these obligations during the Employment Term. All copyrightable works that the Executive creates that relate to
          either the products of the Company or any of its Affiliates or that make use of Confidential Information shall be considered &#8220;work made for hire&#8221; and shall, upon creation, be owned exclusively by the Company. For purposes of this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, &#8220;<font style="font-family: 'Times New Roman';"><u>Intellectual Property</u></font>&#8221; means inventions, discoveries, developments, methods, processes, compositions, works, concepts
          and ideas (whether or not patentable or copyrightable or constituting trade secrets) conceived, made, created, developed or reduced to practice by the Executive (whether alone or with others, whether or not during normal business hours or on or
          off Company premises) during the Executive&#8217;s employment that relate to either the products of the Company or any of its Affiliates or that make use of Confidential Information or any of the equipment or facilities of the Company or any of its
          Affiliates.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Non-disparagement</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">During
          the Employment Term and thereafter, the Executive shall not, directly or indirectly, in his capacity or through any other Person, make negative comments about or otherwise disparage the Company, its Affiliates, or any of their respective
          officers, directors, employees, shareholders, members, agents or products.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Nothing
          contained in this <font style="font-family: 'Times New Roman';"><u>Section 7(e)</u></font> shall preclude the Executive or any of his Affiliates from exercising protected legal rights to the extent that such rights cannot be waived by agreement
          or from providing truthful statements in any filing or submission to any judicial, administrative or arbitral body (including in any deposition held in connection with any proceedings by or before any such Person) or in response to any
          governmental agency, rulemaking authority, subpoena power, legal process, required governmental testimony or filings.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Enforcement</u></font>. The parties acknowledge that a breach of the covenants and agreements contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> would cause
          irreparable damage, the exact amount of which would be difficult to ascertain, and that the remedies at law for any such breach or threatened breach would be inadequate. Accordingly, the Executive agrees that if he breaches or threatens to breach
          any of the covenants or agreements contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, in addition to any other remedy which may be available at law or in equity, the Company and its subsidiaries and
          Affiliates shall be entitled to institute and prosecute proceedings in any court of competent jurisdiction for specific performance and injunctive and other equitable relief to prevent the breach or any threatened breach thereof without bond or
          other security or a showing of irreparable harm or lack of an adequate remedy at law, and an equitable accounting by any court of competent jurisdiction of all profits or benefits arising out of such violation.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-8-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Scope of Covenants; Separate and Independent Covenants</u></font>. The Company and the Executive further acknowledge that the time, scope, geographic area and other provisions of this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> have been specifically negotiated by sophisticated commercial parties and agree that they consider the restrictions and covenants contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> to be reasonable and necessary for the protection of the interests of the Company and its subsidiaries and Affiliates, but if any such restriction or covenant shall be held by any court of competent
          jurisdiction to be void but would be valid if deleted in part or reduced in application, such restriction or covenant shall apply in such jurisdiction with such deletion or modification as may be necessary to make it valid and enforceable. The
          Executive acknowledges and agrees that the restrictions and covenants contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> shall be construed for all purposes to be separate and independent from any other
          covenant, whether in this Agreement or otherwise, and shall each be capable of being reduced in application or severed without prejudice to the other restrictions and covenants or to the remaining provisions of this Agreement. The existence of
          any claim or cause of action by the Executive against the Company or its subsidiaries and Affiliates, whether predicated upon this Agreement or otherwise, shall not excuse the Executive&#8217;s breach of any covenants, agreements or obligations
          contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> and shall not constitute a defense to the enforcement by the Company or any of its subsidiaries of such covenants, agreements and obligations.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Enforceability</u></font>. If any court holds any of the restrictions or covenants contained in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> to be unenforceable by reason
          of their breadth or scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company and its subsidiaries and Affiliates to the relief provided in this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> in the courts of any other jurisdiction within the geographic scope of such restrictions and covenants.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Whistleblower Protection</u></font>. Notwithstanding anything to the contrary contained herein, no provision of this Agreement shall be interpreted so as to impede the Executive (or any other
          individual) from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency
          Inspector General, or making other disclosures under the whistleblower provisions of federal law or regulation. The Executive does not need the prior authorization of the Company to make any such reports or disclosures and the Executive shall not
          be required to notify the Company that such reports or disclosures have been made.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Notices</u></font>. All notices, requests, demands, claims, consents and other communications which are required, permitted or otherwise delivered hereunder shall in every case be in writing and shall
          be deemed properly served if: (a) delivered personally, (b) sent by registered or certified mail, in all such cases with first class postage prepaid, return receipt requested, (c) delivered by a recognized overnight courier service, or (d)
          transmitted by email, to the parties at the addresses as set forth below:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">If to the Company:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Gyre Therapeutics, Inc.</div>
    <div style="text-align: justify; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">12770 High Bluff Drive, Suite 150</div>
    <div style="text-align: justify; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">San Diego, CA 92130 USA</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">With a copy to:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Gibson, Dunn &amp; Crutcher LLP</div>
    <div style="text-align: justify; text-indent: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">555 Mission Street Suite 3000</div>
    <div style="text-align: justify; text-indent: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">San Francisco, CA 94105-0921</div>
    <div style="text-align: justify; text-indent: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Attn: Branden Berns, <u><font style="font-family: 'Times New Roman';">BBerns@gibsondunn.com</font></u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-9-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">If to the Executive:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">At the Executive&#8217;s principal residence address as maintained by the Company in the regular course of its business for payroll purposes</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">or to such other address as shall be furnished in writing by either party to the other party; <font style="font-family: 'Times New Roman';"><u>provided</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>that</u></font> such notice or change in address shall be effective only when actually received by the other party. Date of service of any such notices or other communications shall be: (a) the date such
      notice is personally delivered or transmitted by email (which electronic confirmation of transmission is received), (b) three (3) days after the date of mailing if sent by certified or registered mail, or (c) one (1) business day after date of
      delivery to the overnight courier if sent by overnight courier.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Jurisdiction; Venue</u></font>. Except as otherwise provided in <font style="font-family: 'Times New Roman';"><u>Section 7(f)</u></font> in connection with equitable remedies, each of the parties
          hereto hereby irrevocably submits to the exclusive jurisdiction of any federal or state court located in the State of Delaware over any suit, action, dispute or proceeding arising out of or relating to this Agreement and each of the parties
          agrees that any action relating in any way to this Agreement must be commenced only in the courts located in the State of Delaware, federal or state. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted or not
          prohibited by law, any objection which it may now or hereafter have to the laying of the venue of any such suit, action or proceeding brought in such a court and any claim that any such suit, action or proceeding brought in such a court has been
          brought in an inconvenient forum. Each of the parties hereto hereby irrevocably consents to the service of process in any suit, action or proceeding by sending the same by certified mail, return receipt requested, or by recognized overnight
          courier service, to the address of such party set forth in <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>. With respect to any order obtained in accordance with this <font style="font-family: 'Times New Roman';"><u>Section
              9</u></font>, any party hereto may enforce such order in any court having personal jurisdiction over the party against whom the order shall be enforced.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Waiver of Jury Trial</u></font>. <font style="font-family: 'Times New Roman'; font-weight: bold;">THE PARTIES TO THIS AGREEMENT EACH HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO
            TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I) ARISING UNDER THIS AGREEMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE
            TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES TO THIS AGREEMENT EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR
            CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE
            WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</font></font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-10-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Section 409A</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The
          intent of the parties is that payments and benefits under this Agreement comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder (collectively &#8220;<font style="font-family: 'Times New Roman';"><u>Code
              Section 409A</u></font>&#8221;), and this Agreement and any associated documents shall be interpreted and construed in a manner that establishes an exemption from (or compliance with) the requirements of Code Section 409A. Any terms of this
          Agreement that are undefined or ambiguous shall be interpreted in a manner that complies with Code Section 409A to the extent necessary to comply with Code Section 409A. If for any reason, such as imprecision in drafting, any provision of this
          Agreement (or of any award of compensation, including, without limitation, equity compensation or benefits) does not accurately reflect its intended establishment of an exemption from (or compliance with) Code Section 409A, as demonstrated by
          consistent interpretations or other evidence of intent, such provision shall be considered ambiguous as to its exemption from (or compliance with) Code Section 409A and shall be interpreted in a manner consistent with such intent, as determined
          in the reasonable discretion of the Company. If, notwithstanding the foregoing provisions of this <font style="font-family: 'Times New Roman';"><u>Section 11(a)</u></font>, any provision of this Agreement would cause the Executive to incur any
          additional tax or interest under Code Section 409A, the Company shall, after consulting with the Executive, interpret or reform such provision in a manner intended to avoid the incurrence by the Executive of any such additional tax or interest; <font style="font-family: 'Times New Roman';"><u>provided</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>that</u></font> the Company agrees to maintain, to the maximum extent practicable, the original intent and economic benefit to the
          Executive of the applicable provision without violating the provisions of Code Section 409A.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">A
          termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that the Company determines may be considered nonqualified deferred compensation
          under Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A, and, for purposes of any such provision of this Agreement, references to a
          &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean such a separation from service. The determination of whether and when a separation from service has occurred for purposes of this Agreement shall be made in accordance with the
          presumptions set forth in Section 1.409A-1(h) of the Treasury Regulations.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Notwithstanding
          any other provision of this Agreement, to the extent required to comply with Code Section 409A (as determined by the Company), if the Executive is a &#8220;specified employee,&#8221; as determined by the Company, as of his date of termination, then all
          amounts due under this Agreement that constitute a &#8220;deferral of compensation&#8221; within the meaning of Code Section 409A, that are provided as a result of a &#8220;separation from service&#8221; within the meaning of Code Section 409A, and that would otherwise
          be paid or provided during the first six months following the Executive&#8217;s date of termination, shall be accumulated through and paid or provided on the first business day that is more than six months after the Executive&#8217;s date of termination (or,
          if the Executive dies during such six month period, within 90 days after Executive&#8217;s death).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Any
          reimbursements provided under this Agreement that constitute deferred compensation within the meaning of Code Section 409A shall be made or provided in accordance with the requirements of Code Section 409A, including, without limitation, that (i)
          in no event shall any fees, expenses or other amounts eligible to be reimbursed by the Company under this Agreement be paid later than the last day of the calendar year next following the calendar year in which the applicable fees, expenses or
          other amounts were incurred; (ii) the amount of expenses eligible for reimbursement in any given calendar year shall not affect the expenses that the Company is obligated to reimburse in any other calendar year, provided that the foregoing clause
          (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect; (iii) the Executive&#8217;s right
          to have the Company pay or provide such reimbursements may not be liquidated or exchanged for any other benefit; and (iv) in no event shall the Company&#8217;s obligations to make such reimbursements apply later than the Executive&#8217;s remaining lifetime
          (or if longer, through the sixth (6th) anniversary of the Commencement Date).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-11-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">For
          purposes of Code Section 409A, the Executive&#8217;s right to receive any installment payments shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with
          reference to a number of days (for example, &#8220;payment shall be made within thirty (30) days following the date of termination&#8221;), the actual date of payment within the specified period shall not be within the discretion of the Executive. In no
          event may the Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement, to the extent such payment is subject to Code Section 409A.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The
          Company makes no representation or warranty and shall have no liability to the Executive or any other Person if any provisions of this Agreement are determined to constitute deferred compensation subject to Code Section 409A but do not satisfy an
          exemption from, or the conditions of, Code Section 409A.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Excise Taxes</u></font>. Notwithstanding anything to the contrary in this Agreement, if the Executive is a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code), and the payments and
          benefits provided for under this Agreement, together with any other payments and benefits which the Executive has the right to receive from the Company of any of its Affiliates, would constitute a &#8220;parachute payment&#8221; (as defined in Section
          280G(b)(2) of the Code), then the payments and benefits provided for under this Agreement shall be either (a) reduced (but not below zero) so that the present value of such total amounts and benefits received by the Executive from the Company and
          its Affiliates will be one dollar ($1.00) less than three times the Executive&#8217;s &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code) and so that no portion of such amounts and benefits received by the Executive shall be subject to the
          excise tax imposed by Section 4999 of the Code or (b) paid in full, whichever produces the better net after-tax position to the Executive (taking into account any applicable excise tax under Section 4999 of the Code and any other applicable
          taxes). The reduction of payments and benefits hereunder, if applicable, shall be made by reducing, first, payments or benefits to be paid in cash hereunder in the order in which such payment or benefit would be paid or provided (beginning with
          such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time) and, then, reducing any benefit to be provided in kind hereunder in a similar
          order. The determination as to whether any such reduction in the amount of the payments and benefits provided hereunder is necessary shall be made by a nationally recognized public accounting firm selected by the Company in good faith and
          approved by the Executive, which approval shall not be unreasonably withheld. If a reduced payment or benefit is made or provided and through error or otherwise that payment or benefit, when aggregated with other payments and benefits from the
          Company or its Affiliates used in determining if a parachute payment exists, exceeds one dollar ($1.00) less than three times the Executive&#8217;s base amount, then the Executive shall immediately repay such excess to the Company upon notification
          that an overpayment has been made.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-12-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>General</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Governing Law</u></font>. This Agreement and the legal relations thus created between the parties hereto shall be governed by, and construed in accordance
          with, the internal laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any
          jurisdiction other than the State of Delaware.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Construction and Severability</u></font>. Whenever possible, each provision of this Agreement shall be construed and interpreted in such manner as to be
          effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by, or invalid, illegal or unenforceable in any respect under, any applicable law or rule in any jurisdiction, such prohibition, invalidity,
          illegality or unenforceability shall not affect any other provision of this Agreement or any other jurisdiction, and the parties undertake to implement all efforts which are necessary, desirable and sufficient to amend, supplement or substitute
          all and any such prohibited, invalid, illegal or unenforceable provisions with enforceable and valid provisions in such jurisdiction which would produce as nearly as may be possible the result previously intended by the parties without
          renegotiation of any material terms and conditions stipulated herein.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Cooperation</u></font>. During the Employment Term and five (5) years thereafter, the Executive shall reasonably cooperate with the Company and be reasonably available to the Company with respect to
          continuing and/or future matters related to the Executive&#8217;s Employment Term with the Company and/or its subsidiaries or Affiliates, whether such matters are business-related, legal, regulatory or otherwise (including, without limitation, the
          Executive appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are
          or may come into the Executive&#8217;s possession); provided that, the Company shall make reasonable efforts to minimize disruption of the Executive&#8217;s other activities. The Company shall reimburse the Executive for any reasonable travel and other
          expenses that he incurs on the Company&#8217;s behalf as a result of compliance with this <font style="font-family: 'Times New Roman';"><u>Section 13(c)</u></font>, after receipt of appropriate documentation consistent with the Company&#8217;s business
          expense reimbursement policy.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Successors and Assigns</u></font>. This Agreement shall bind and inure to the benefit of and be enforceable by the Company and its successors and assigns and the Executive and the Executive&#8217;s heirs,
          executors, administrators, and successors; <font style="font-family: 'Times New Roman';"><u>provided</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>that</u></font> the services provided by the Executive under this Agreement are of a
          personal nature, and the Executive may not sell, convey, assign, delegate, transfer or otherwise dispose of, directly or indirectly, any of the rights, claims, powers, interests or obligations of the Executive under this Agreement; <font style="font-family: 'Times New Roman';"><u>provided</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>further</u></font> that the Company may assign this Agreement to, and all rights hereunder shall inure to the benefit of, any
          subsidiary or Affiliate of the Company or any Person, firm or corporation resulting from the reorganization of the Company or succeeding to the business or assets of the Company by purchase, merger, consolidation or otherwise and, in such event,
          all references herein to the Company shall refer to such assignee; <font style="font-family: 'Times New Roman';"><u>provided</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>further</u></font> that such surviving, resulting, or
          acquiring entity shall in writing assume and agree to perform all of the obligations of the Company under this Agreement. Any purported assignment of this Agreement in violation of the foregoing shall be null and void.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-13-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Executive&#8217;s Representations</u></font>. The Executive hereby represents and warrants to the Company that: (i) the execution, delivery and performance of this Agreement by the Executive do
          not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which the Executive is a party or by which the Executive is bound; (ii) the Executive is not a party to or
          bound by any employment agreement, noncompetition or nonsolicitation agreement or confidentiality agreement with any other Person or entity besides the Company; (iii) the Executive is not subject to any restriction whatsoever that would cause him
          to not be able fully to fulfill his duties under this Agreement; (iv) the Executive is not a party to, or involved in, or under investigation in, any pending or, to the best of the Executive&#8217;s knowledge, threatened litigation, proceeding or
          investigation of any governmental body or authority or any other Person; (v) the Executive has never been suspended, censured or otherwise subjected to any disciplinary action or other proceeding by any state, other Governmental Entity, agency or
          self-regulatory organization and (vi) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of the Executive, enforceable in accordance with its terms. <font style="font-family: 'Times New Roman'; font-weight: bold;">THE EXECUTIVE HEREBY ACKNOWLEDGES AND REPRESENTS THAT THE EXECUTIVE HAS CONSULTED WITH INDEPENDENT LEGAL COUNSEL REGARDING THE EXECUTIVE&#8217;S RIGHTS AND OBLIGATIONS UNDER THIS AGREEMENT TO
            THE EXTENT DETERMINED NECESSARY OR APPROPRIATE BY THE EXECUTIVE, AND THAT THE EXECUTIVE FULLY UNDERSTANDS THE TERMS AND CONDITIONS CONTAINED HEREIN.</font></font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Compliance with Rules and Policies</u></font>. The Executive shall perform all services in accordance with the lawful policies, procedures and rules established by the Company and the
          Board, provided that such policies, procedures and/or rules are made available to the Executive in writing. In addition, the Executive shall comply with all laws, rules and regulations that are generally applicable to the Company or its
          subsidiaries or Affiliates and their respective employees, directors and officers.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Forfeiture</u></font>. Notwithstanding any other provision of this Agreement to the contrary, any payments or benefits under this Agreement or any incentive or other compensation plan or program of the
          Company or its Affiliates shall be subject to any forfeiture, repayment or recoupment policy of the Company, as in effect from time to time, that are required by applicable law.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Withholding Taxes</u></font>. All amounts payable hereunder shall be subject to the withholding of all applicable taxes and deductions required by any applicable law.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Entire Agreement</u></font>. This Agreement constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and terminates and
          supersedes any and all prior agreements, understandings and representations, whether written or oral, by or between the parties hereto or their current or former Affiliates which relate or may have related to the provision of services in any way,
          and any other existing employment, consulting or change of control agreement, which are hereby terminated and cancelled and of no further force or effect as of the date hereof, without the payment of any additional consideration by or to either
          of the parties hereto. The Executive acknowledges that no representations, warranties, promises, covenants, agreements or obligations, oral or written, have been made other than those expressly stated herein, and in the other documents delivered
          by the parties in connection herewith, and that he has not relied on any other representations, warranties, promises, covenants, agreements or obligations in signing this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-14-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Duration</u></font>. Notwithstanding the Employment Term hereunder, this Agreement shall continue for so long as any obligations remain under this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(k)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Survival</u></font>. The provisions of <font style="font-family: 'Times New Roman';"><u>Sections 6</u></font>, <font style="font-family: 'Times New Roman';"><u>9</u></font>, <font style="font-family: 'Times New Roman';"><u>10</u></font>, <font style="font-family: 'Times New Roman';"><u>11</u></font>, <font style="font-family: 'Times New Roman';"><u>12</u></font> and <font style="font-family: 'Times New Roman';"><u>13</u></font>
          of this Agreement shall survive and shall continue to be binding upon the Executive notwithstanding the termination of this Agreement for any reason whatsoever.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(l)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Amendment; Modification; Waiver</u></font>. The provisions of this Agreement may be modified, amended or waived only in a document signed by the parties hereto and referring specifically
          hereto, and no handwritten changes to this Agreement will be binding unless initialed by each party. No course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this
          Agreement (including, without limitation, the Company&#8217;s right to terminate the Agreement for Cause) shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any similar or dissimilar
          requirement, provision or condition of this Agreement at the same or any prior or subsequent time. Pursuit by either party of any available remedy, either in law or equity, or any action of any kind, does not constitute waiver of any other remedy
          or action. Such remedies and actions are cumulative and not exclusive.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Counterparts</u></font>. This Agreement may be executed by the parties in counterparts, each of which shall be an original and all of which taken together shall constitute one instrument.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(n)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Section References</u></font>. Section headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose. The
          words Section and paragraph herein shall refer to provisions of this Agreement unless expressly indicated otherwise.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(o)</font><font style="font-size: 10pt;">&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>No Strict Construction</u></font>. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be
          construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring either party hereto by virtue of the authorship of any of the provisions of this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(p)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>No Third-Party Beneficiaries</u></font>. Nothing in this Agreement, express or implied, is intended or shall be construed to give any Person other than the parties to this Agreement and
          their respective heirs, executors, administrators, successors or permitted assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">[END OF TEXT &#8211; SIGNATURE PAGE FOLLOWS]</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-15-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have hereunto executed this Agreement as of the day and year first written
      above.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zc31daa3dfeab4222afac09b3a19a56a5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">COMPANY:</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">GYRE THERAPEUTICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">Date:<font style="font-family: 'Times New Roman';"><u> <br>
                </u></font></div>
          </td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';">January 15, 2024</font></td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:<font style="font-family: 'Times New Roman';"> <br>
              </font></div>
          </td>
          <td style="width: 47%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';">/s/ Ruoyu Chen</font></td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Ruoyu Chen</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">EXECUTIVE:</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">Date:<font style="font-family: 'Times New Roman';"><u> <br>
                </u></font></div>
          </td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';">January 15, 2024</font></td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">/s/ Han Ying</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Han Ying</div>
          </td>
        </tr>

    </table>
    <div style="text-align: left; font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>gyre-20231211.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<xs:schema targetNamespace="http://ir.catalystbiosciences.com/20231211" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:gyre="http://ir.catalystbiosciences.com/20231211" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="gyre-20231211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gyre-20231211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>gyre-20231211_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>gyre-20231211_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="gyre-20231211.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139710384986848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 11,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gyre Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12770 High Bluff Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949-3681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GYRE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>ef20019132_8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gyre-20231211.xsd" xlink:type="simple"/>
    <context id="c20231211to20231211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20231211to20231211"
      id="Fact_31431eae65574d029d1bb18e2d8f363f">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20231211to20231211"
      id="Fact_715a27db599444ffa760a2e5adc48c09">0001124105</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20231211to20231211"
      id="Fact_e338b480561949179b54e82ead96a3d4">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20231211to20231211"
      id="Fact_4ad4d7bed0d541a5884618667ea24440">2023-12-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20231211to20231211"
      id="Fact_94e592c3c7434260a80c7e0be88622d6">Gyre Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20231211to20231211"
      id="Fact_5aea80d44c2443688a278cf11e5ba6e7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20231211to20231211"
      id="Fact_19c105802de6462bb420ed4e4ac05b54">000-51173</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20231211to20231211"
      id="Fact_6f0d2c0f746a45b2b60496cd399d7a46">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20231211to20231211"
      id="Fact_1f82017e2439400b9da329d7adb130db">12770 High Bluff Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20231211to20231211"
      id="Fact_4509eaad04094187b871a2a62dbfa7d9">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20231211to20231211"
      id="Fact_bbe31d698a074fa4ac60f4d6f43a1952">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20231211to20231211"
      id="Fact_b2d1e3af847a40048d7c248eba4e59a7">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20231211to20231211"
      id="Fact_ec5016c69836479091e938597c4917d1">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20231211to20231211"
      id="Fact_33bdfe32d3f24326b0dc92f0012f7ac5">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20231211to20231211"
      id="Fact_d0d31ab9b9cb4ba3951215bb6dc82046">949-3681</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20231211to20231211"
      id="Fact_1f745627c6654c6895325876c6365610">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20231211to20231211"
      id="Fact_4f7caaeed54a4ccc881dc2d1982d9605">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20231211to20231211"
      id="Fact_37ea596f70db409d8bbd88918a944f34">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20231211to20231211"
      id="Fact_9d0db4d3aafa4c50a7c70baa8c517c39">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20231211to20231211"
      id="Fact_6eb13dac33fd492eaf6a26ccfdc5f110">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231211to20231211"
      id="Fact_e636396c875741c3bf176385e303456c">GYRE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20231211to20231211"
      id="Fact_0f2de5a65ab5457cbff86b15b7b7f598">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20231211to20231211"
      id="Fact_8e548309691b45f8abf8051e94c31cb9">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *V ,U@D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *V ,UAED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20019132_8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" isOnlyDei="true" isUsgaap="true" original="ef20019132_8ka.htm">ef20019132_8ka.htm</File>
    <File>gyre-20231211.xsd</File>
    <File>gyre-20231211_lab.xml</File>
    <File>gyre-20231211_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20019132_8ka.htm": {
   "nsprefix": "gyre",
   "nsuri": "http://ir.catalystbiosciences.com/20231211",
   "dts": {
    "inline": {
     "local": [
      "ef20019132_8ka.htm"
     ]
    },
    "schema": {
     "local": [
      "gyre-20231211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gyre-20231211_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gyre-20231211_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20231211to20231211",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20019132_8ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231211to20231211",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20019132_8ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001140361-24-002903-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-002903-xbrl.zip
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M_V=7V7_<K6@9A^7;UHEZ81[N$8J]94H/+ND%KQUCJ/07'+#&87@Y2F%UQT-
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M%"$G'@Q63XO\A\1K>+4$9^H>H"K+U+ +<3W#W1\O;ZG&63$//!HP,Q0P/.
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MXN/-!-?A70HOXLD=+AE;AP-4.,GX&R+*.TI&VK^G9*3[KO(9?4JQ<.<\^10
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M,C$Q+GAS9+5776_;(!1]G[3_P/R./^*V:J*FU::V4Z5NG;I-VMM$,';0"'A
MVN3?#[!QG,_%\?8&W'O./?=RP?CJ9C%CX(5(104?!TD8!X!P+#+*BW$P5Q I
M3&EP<_WVS=4["#\23B32) .3)?@@!<HDS0H"OCP_Y901,$C#9! FX7ER>=&R
M0VCQ"S52>$IF"&@D"Z(_HQE1)<)D'$RU+D=11&6(D49LJ?2$"A/92"$JQ&(6
M#>)!F@R2Q,AC9$:XOA=R=DMR-&=Z'/R>(T9S2K( F'RX&BU40_KZ^AJ^IJ&0
MA2&)D^C'I\>O3H;W+9:RHX0*QRC_M19E,9',QTDC:YX@11I)6_ZUJF0X'$;.
MVK@:(GJ FG*ED='5]L]T V@[GT>5T;MFA*[[*8+#0KQ$QN R;!RUA'I9$K5;
MAS%'UFPQ QBG,&WJ8KIF'9@C-7$@;UD+I*3>Y]^8*H!I(@!L&R'.A4;:M*Q;
MJA?+DO)<U"MFS59TY'?AF>3 U7AD"<>!HK.2V0*ZM:DD^3BPC0#]+O\L)0F-
M0N\B!2,'ML2:(P-1IC6=LL=58$^!)-YBV>H!0R)*(C4U6:]:*/IG:3$TZ9J6
M@1#V?_.Q/-],!L .OC\_'',>G;9;@>?V.GC/LSNNJ5X^F!Z0,[<% :#9.#CH
MT<CP0C*24TY=:\7FMHAC (%G: \1ST!%!UI\5]$FR2;_7)'LB5^[\6:[U.C:
MY1 2(X;G[ 3@2ME^7+WJM\0?L6CCC%4+ZR?1GD/3@4)JP+=N]_8U4"!4UK=
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M=SB6UN*2?>)O_BV:POQ-N;/_ 5!+ P04    " "M@#-837*W0.D%   ./P
M%0   &=Y<F4M,C R,S$R,3%?<')E+GAM;-5;WV_B.!!^/^G^AQS[#&G@MK=4
M95>];KM"VVU1Z>E^O)Q,8L"Z)$9.:.&_/SO8+79L)VS;U?2EA<SG\<Q\7^QD
M2$X_;;(TN,>L(#0?=:+>42? >4P3DB]&G771145,2.?3QY]_.OVEV_V"<\Q0
MB9-@M@U^9Q0EC"0+'$QN;^8DQ4%_T(OZO:CW/OIPO&?O=L7XE.3_G8@_,U3@
M@,^;%R>;@HPZR[)<G83AP\-#[V'0HVP1]H^.HO"O;U?3>(DSU"5Y4:(\QIV
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M5_C]EA+HMY1 _RU)P$SJ.R70?Y( Y!Z?*_Q!2PD,6DI@\)8D8";UG1(8/$D
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M1?P1KW!__!]02P$"% ,4    " "M@#-8%U></.P7  "ZCP  $@
M    @ $     968R,# Q.3$S,E\X:V$N:'1M4$L! A0#%     @ K8 S6%(=
M4\3:2@   94! !4              ( !'!@  &5F,C P,3DQ,S)?97@Q,"TQ
M+FAT;5!+ 0(4 Q0    ( *V ,U@[/XWE30,  &0/   1              "
M 2EC  !G>7)E+3(P,C,Q,C$Q+GAS9%!+ 0(4 Q0    ( *V ,UB-!,],@ @
M '58   5              "  :5F  !G>7)E+3(P,C,Q,C$Q7VQA8BYX;6Q0
M2P$"% ,4    " "M@#-837*W0.D%   ./P  %0              @ %8;P
K9WER92TR,#(S,3(Q,5]P<F4N>&UL4$L%!@     %  4 2 $  '1U      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
